QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.057893v1 309/1/369    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Onyia, J. E. Articles by Martin, T. J. Search for Related Content PubMed PubMed Citation Articles by Onyia, J. E. Articles by Martin, T. J.

ENDOCRINE AND REPRODUCTIVE

Novel and Selective Small Molecule Stimulators of Osteoprotegerin Expression Inhibit Bone Resorption

Gene Regulation, Bone and Enabling Biology (J.E.O., R.J.S.G., Y.L.M., D.L.H., R.R.M., X.Y., T.F., R.L.C., Q.Q.Z., S.C., K.T., H.U.B.), Lead Generation Biology (R.E.), and Discovery Chemistry Research (Y.X.), Lilly Research Labs, Eli Lilly and Company, Indianapolis, Indiana; and St. Vincent's Institute of Medical Research (T.J.M.), Fitzroy, Victoria, Australia

Osteoprotegerin (OPG), a secreted member of the tumor necrosis factor receptor superfamily, is a potent inhibitor of osteoclast formation and bone resorption. Because OPG functions physiologically as a locally generated (paracrine) factor, we used high-throughput screening to identify small molecules that enhance the activity of the promoter of the human OPG gene. We found three structurally unrelated compounds that selectively increased OPG gene transcription, OPG mRNA levels, and OPG protein production and release by osteoblastic cells. Structural analysis of one compound, a benzamide derivative, led to the identification of four related molecules, which are also OPG inducers. The most potent of these compounds, Cmpd 5 inhibited osteoclast formation and parathyroid hormone-induced calvarial bone resorption. In vivo, Cmpd 5 completely blocked resorptive activity (serum calcium, osteoclast number) in parathyroid hormone-treated rats. Furthermore, Cmpd 5 reduced the ability of a rat breast cancer to metastasize to bone. Finally, the compound also prevented bone loss in a rat adjuvant arthritis model. These results provide proof of the concept that low molecular weight compounds can enhance OPG production in ways that can result in effective therapies.

Address correspondence to: Dr. Rachelle J. S. Galvin, BLDG 98C/B, DC 0403, Lilly Research Labs, Eli Lilly and Company, Indianapolis, IN 46285. E-mail: RJSGalvin{at}lilly.com

This article has been cited by other articles:

				T. J. Martin and K. W. Ng New Agents for the Treatment of Osteoporosis IBMS BoneKEy, November 1, 2007; 4(11): 287 - 298. [Abstract] [Full Text] [PDF]

				T. J. Martin Current, New and Emerging Anti-Resorptive Drugs; Antibody Blockade Of RANKL Action IBMS BoneKEy, May 1, 2006; 3(5): 42 - 46. [Full Text] [PDF]

				T. J. Martin New Aspects of Wnt Signalling Revealed by Mouse and Human Genetics IBMS BoneKEy, October 1, 2005; 2(10): 7 - 11. [Full Text] [PDF]

				L. C. Hofbauer and M. Schoppet Clinical Implications of the Osteoprotegerin/RANKL/RANK System for Bone and Vascular Diseases JAMA, July 28, 2004; 292(4): 490 - 495. [Abstract] [Full Text] [PDF]